Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T17:06:48.610Z.
Calculation as of: 2026-10-06T17:06:48.610Z.
Quote observation: 2026-10-06T17:02:24.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 2d15fccd73dd71321fa30efb235d10704747171fee005d1a5dd6499fafc6c703
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
Market Cap
$17.14M
PS Ratio
1.30
TTM Avg
1.77
3Y Avg
177.00
5Y Avg
2050.99
Market Cap
$18.65M
PS Ratio
15.88
TTM Avg
3.71
3Y Avg
52.88
5Y Avg
45311.56
Market Cap
$16.50M
PS Ratio
4.75
TTM Avg
10.56
3Y Avg
13.22
5Y Avg
19.14
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Estrella Immunopharma, Inc. (ESLA) | $17.60M | N/A | N/A | N/A | N/A |
| Cosmos Health Inc. (COSM)vs › | $17.72M | 0.24 | 0.24 | 0.25 | 0.35 |
| PAVmed Inc. (PAVM)vs › | $17.23M | 153.88 | 160.63 | 60.23 | 135.95 |
| Lipocine Inc. (LPCN)vs › | $17.15M | 10.93 | 9.03 | 16.06 | 157.58 |
| Palatin Technologies, Inc. (PTN)vs › | $17.14M | 1.30 | 1.77 | 177.00 | 2050.99 |
| Marker Therapeutics, Inc. (MRKR)vs › | $17.01M | 13.79 | 9.33 | 7.96 | 8.85 |
| Bionano Genomics, Inc. (BNGO)vs › | $16.52M | 0.55 | 0.37 | 0.68 | 11.87 |
| Neuphoria Therapeutics Inc. (NEUP)vs › | $18.65M | 15.88 | 3.71 | 52.88 | 45311.56 |
| Dyadic International, Inc. (DYAI)vs › | $16.50M | 4.75 | 10.56 | 13.22 | 19.14 |
| Karyopharm Therapeutics Inc. (KPTI)vs › | $16.08M | 0.11 | 0.76 | 0.68 | 1.36 |
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-12 |
| Q4 FY2025Period ended 2025-12-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-03-18 |
| Q1 FY2026Period ended 2026-03-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-18 |
| Q2 FY2026Period ended 2026-06-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-13 |
| TTM revenue | $0 |
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
